ViaDerma (ViaDerma) EBIT : $3.76 Mil (TTM As of Jun. 2012)

View and export this data going back to 2008. Start your Free Trial

What is ViaDerma EBIT?

ViaDerma's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2012 was $1.52 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2012 was $3.76 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ViaDerma's annualized ROC % for the quarter that ended in Jun. 2012 was 10.58%. ViaDerma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2012 was 14.95%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ViaDerma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2012 was 52.47%.

ViaDerma EBIT Historical Data

The historical data trend for ViaDerma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViaDerma EBIT Chart

ViaDerma Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

EBIT

-0.14

9.01

6.40

7.77

4.05

ViaDerma Quarterly Data
	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12
EBIT	Get a 7-Day Free Trial															1.56	0.70	0.81	0.73	1.52

Competitive Comparison of ViaDerma's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, ViaDerma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ViaDerma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ViaDerma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ViaDerma's EV-to-EBIT falls into.

ViaDerma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.76 Mil.

ViaDerma (OTCPK:VDRM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ViaDerma's annualized ROC % for the quarter that ended in Jun. 2012 is calculated as:

	ROC % (Q: Jun. 2012 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2012 )	+	Invested Capital (Q: Jun. 2012 ))	/ count )
=	6.084 * ( 1 - 28.75% )	/	( (40.786	+	41.193)	/ 2 )
=	4.33485	/	40.9895
=	10.58 %

where

	Invested Capital		(Q: Mar. 2012 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	44.93	-	2.774	-	( 1.37	-	max(0, 7.719	-	17.218	+	1.37	))
=	40.786

	Invested Capital		(Q: Jun. 2012 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	45.832	-	3.452	-	( 1.187	-	max(0, 7.872	-	16.925	+	1.187	))
=	41.193

Note: The Operating Income data used here is four times the quarterly (Jun. 2012) data.

2. Joel Greenblatt's definition of Return on Capital:

ViaDerma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2012 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2012 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2012		Q: Jun. 2012
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	6.092	/	( ( (27.712 + max(12.579, 0))	+	(28.908 + max(12.286, 0)) )	/	2 )
=	6.092	/	( ( 40.291	+	41.194 )	/	2 )
=	6.092	/	40.7425
=	14.95 %

where Working Capital is:

	Working Capital		(Q: Mar. 2012 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(13.304	+	0.334	+	2.21)	-	(2.774	+	0	+	0.495)
=	12.579

	Working Capital		(Q: Jun. 2012 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(14.132	+	0.612	+	0.994)	-	(3.452	+	0	+	0)
=	12.286

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2012) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ViaDerma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2012 )
	=	3.755	/	7.156
	=	52.47 %

ViaDerma EBIT Related Terms

Thank you for viewing the detailed overview of ViaDerma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

ViaDerma (ViaDerma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ViaDerma Inc (OTCPK:VDRM) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

4640 Admiralty Way, Suite 500, Marina Del Rey, CA, USA, 90292

Website

https://www.viaderma.com

ViaDerma Inc is a specialty pharmaceutical company focused to bring new products to market through research and development. It is engaged in the business of manufacturing and sales of pharmaceuticals, and specifically topical antibiotics and pain management in the United States of America. Its sells under the brand name Vitastem. The Company also has products in development in the fields; anti-aging skin care, pain management, hair-loss, and toenail fungus.